

2017 UK Therapeutic Drug Monitoring (TDM) Market: Future Horizons and Growth Strategies--Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities

<https://marketpublishers.com/r/U3EFBAF5C95EN.html>

Date: March 2017

Pages: 247

Price: US\$ 2,205.00 (Single User License)

ID: U3EFBAF5C95EN

Abstracts

This new 247-page report from VPGMarketResearch.com provides a comprehensive analysis of the UK therapeutic drug monitoring market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers. The report provides test volume and sales forecasts by country and market segment for the following assays: Amikacin, Carbamazepine, Cyclosporin, Digoxin, Everolimus, Gentamicin, Levetiracetam, Lithium, Methotrexate, NAPA/Procainamide, Phenobarbital, Phenytoin, Quinidine, Sirolimus, Tacrolimus, Theophylline, Tobramycin, Topiramate, Valproic Acid and Vancomycin. During the next five years, the TDM market will undergo significant transformation. These changes will be caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition.

Some segments will start resembling commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others. This report is a unique market and technology assessment designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities and developed effective strategic responses. The study provides five-year forecasts for major TDM assays; compares features of leading analyzers; and profiles key competitors.

Contains 247 pages and 17 tables

Contents

I. INTRODUCTION

II. WORLDWIDE MARKET OVERVIEW

1. MARKET OVERVIEW
2. WORLDWIDE MARKET STRUCTURE
3. WORLDWIDE MARKET SIZE AND GROWTH

III. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

- A. Reagent Kits and Test Systems/Panels
- B. Instrumentation
- C. Computers, Software and Automation
- D. Auxiliary Products

IV. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

V. ALTERNATIVE MARKET PENETRATION STRATEGIES

- A. Internal Development
- B. Collaborative Arrangements
- C. University Contracts
- D. Distribution Strategies

VI. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

- A. Market Maturity
- B. Cost Containment
- C. Competition
- D. Technological Edge and Limitations
- E. Patent Protection
- F. Regulatory Constraints
- G. Decentralized Testing Market Challenges

VII. WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW

- A. Cancer Statistics and Etiology

1. BREAST CANCER
2. LUNG CANCER
3. COLON AND RECTUM CANCER
4. PROSTATE CANCER
5. STOMACH CANCER
6. LEUKEMIA
7. LYMPHOMA
8. ORAL CANCER
9. SKIN CANCER
10. UTERINE CANCER
11. OESOPHAGIAN CANCER
12. BLADDER CANCER

B. Major Current And Emerging Cancer Diagnostic Tests

1. INTRODUCTION
2. TUMOR MARKER CLASSIFICATION
3. ACTH
4. ALPHA-FETOPROTEIN (AFP)
5. BETA-2 MICROGLOBULIN
6. CA 15-3/27.29
7. CA 19-9
8. CA-125
9. CALCITONIN
10. CARCINOEMBRYONIC ANTIGEN (CEA)
11. ESTROGEN AND PROGESTERONE RECEPTORS
12. FERRITIN
13. GASTRIN
14. HUMAN CHORIONIC GONADOTROPIN (HCG)
15. INSULIN
16. NSE
17. OCCULT BLOOD
18. PAP SMEAR/HP5
19. PROSTATIC ACID PHOSPHATASE (PAP)
20. PROSTATE-SPECIFIC ANTIGEN (PSA)
21. SQUAMOUS CELL CARCINOMA ANTIGEN (SCC)
22. T AND B LYMPHOCYTES
23. TDT
24. THYROGLOBULIN
25. TISSUE POLYPEPTIDE ANTIGEN (TPA)
26. BIOCHEMICAL TUMOR MARKERS

27. ONCOGENES

Abl/abl-bcr

A1B1

BCL-2

BRCA1

CD44

C-fos

C-myb

C-myc

CYP-17

Erb-B

HPC1

N-myc

P40

P51

P53

P1K3CA

PT1-1

Ras

Reg

Sis

Src

28. POLYPEPTIDE GROWTH FACTORS

Basic Fibroblast Growth Factor

Beta-TGF

Cachectin (TNT)

Calmodulin

ECFR

Nerve Growth Factor (NGF)

Epidermal Growth Factor (EGF)

Ornithine Decarboxylase

Transferrin

Transforming Growth Factor-Alpha

29. ENDOCRINE HORMONES

30. COLONY STIMULATING FACTORS

31. LYMPHOKINES

Alpha-1 Interferon

B Cell Growth Factors

B Cell Growth Factor (BCGF)

Gamma-1nterferon
1nterleukin-1 (1L-1)
Macrophage Activating Factor
32. 1MMUNOH1STOCHEM1CAL STA1NS
33. EMERG1NG TUMOR MARKERS
N-Acetylglucosamine
Actin
Alpha-Actin
Antineuronal Antibodies
7B2
B72.3
Bax
BCD-F9
BLCA-4
Blood Group Antigens A,B,H
CA
CA 72-4/TAG-72
CA
CA-242
CA-549
CAM
CAR-3
Cathepsin-D
Chromogranin A and B
Cluster 1 Antigen
Cluster-5/5A Antigen
CTA
CU18
DR-70
DU-PAN-2
Endometrial Bleeding Associated Factor
Endostatin
Epithelial Membrane Antigen
Feulgen Hydrolysis
Fibronectin
FSH
(1->3)-L-fucosyltransferase
Gastrin-Releasing Peptide (GRP)
GDCFP-15

Glucagon
Glycoamines
H23
Her-2
Human Carcinoma Antigen
HPA
HSP27
Intermediate Filaments
Cytokeratins/CK18/Cyfra 21-1
Desmin
Gliofibrillary Acid Protein
Neurofilaments
Sildenafil
KA
Kinases
KP16D3
LA1
Leukocyte Common Antigen
Lewis Antigens
Lysophosphatidic Acid (LPA)
Ma 695/Ma
MABDF3
MAG
ME1
Minactivin
MN/CA9
MSA
Mucin Cancer Antigen (MCA)
Multiple Tumor Suppressor
Myosin
NEA-130
NMP22
OA-519
Opioid Peptides
P-glycoprotein
Pancreatic Oncofetal Antigen (POA)
Placental Lactogen
PR92
Proliferative Index, Ki-67

Px
RB 1nactivation/Deletion
Ret
SCCL
Selectin
Sialic AcHSP27

1Intermediate Filaments
Cytokeratins/CK18/Cyfra 21-1
Desmin
Gliofibrillary Acid Protein
Neurofilaments
5imentin

KA

Kinases

KP16D3

LA1

Leukocyte Common Antigen
Lewis Antigens
Lysophosphatidic Acid (LPA)
Ma 695/Ma

MABDF3

MAG

ME1

Minactivin

MN/CA9

MSA

Mucin Cancer Antigen (MCA)
Multiple Tumor Suppressor
Myosin

NEA-130**NMP22****OA-519**

Opioid Peptides
P-glycoprotein
Pancreatic Oncofetal Antigen (POA)
Placental Lactogen

PR92

Proliferative Index, Ki-67
Px
RB 1 inactivation/Deletion
Ret

SCCL

Selectin
Sialic Acid
Sialyl SSEA-1/SL10

SN10

Somatostatin

TA-90**TABA**

Tachykinin

TAG

TPS

Troponin

Tubulin

5CAM**5EGF**

5illen

C. Cancer Diagnostic Testing Instrumentation Review and Market Needs

D. Current and Emerging Cancer Diagnostic Technologies

1. MONOCLONAL AND POLYCLONAL ANTIBODIES
2. IMMUNOASSAYS
3. MOLECULAR DIAGNOSTICS
4. CHROMOSOME ANALYSIS
 - a. Chronic Myelogenous Leukemia (CML)
 - b. Acute Myeloid Leukemia (AML)
 - c. Acute Lymphoblastic Leukemia (ALL)
 - d. Malignant Lymphomas Lymphoid Malignancies
 - e. Chronic Lymphocytic Leukemia (CLL)
 - f. Solid Cancers
 - g. Chromosomal Translocation and Oncogenes
5. ARTIFICIAL INTELLIGENCE
6. FLOW CYTOMETRY
7. TWO DIMENSIONAL GEL ELECTROPHORESIS (2-DGE)
8. BIOSENSORS
9. COMPETING/COMPLEMENTING TECHNOLOGIES

E. Personal Testing

VIII. UK CANCER DIAGNOSTICS MARKET

A. Executive Summary

B. Business Environment

C. Market Structure

D. Market Size, Test Volume and Sales Forecasts by Market Segment, Major Supplier Sales and Market Shares by Test

IX. COMPETITIVE PROFILES

Abbott
AdnaGen/Alere
Agilent Technologies
Applied Gene Technologies
Arca Biopharma
Beckman Coulter/Danaher
Becton Dickinson
Biomedical Diagnostics
bioMerieux
Bio-Rad
CellSearch
Cepheid
Correlogic Systems/5ermillion
Decode Genetics
Diadexus
Diagnocure
Diasorin
Eiken Chemical
Elitech Group
Enterix
Enzo Biochem
Epigenomics
Exact Sciences
Fujirebio
Guided Therapeutics
Hologic/Gen-Probe
Kreatech/Leica
Kyowa Medex
Mackay Life Sciences
Myriad Genetics
OncoLab
Ortho-Clinical Diagnostics
Panacea Pharmaceuticals
Polartechnics
Polymedco
PreMD
Qiagen

Quest Diagnostics
Radiant Pharmaceuticals
Roche
Scienion
Sequenom
Siemens Healthcare
Takara Bio
Targeted Diagnostics & Therapeutics
Tosoh
Thermo
5eridex
Wako Pure Chemicals
Wallac/PE
Zila

X. APPENDIX: MAJOR UNIVERSITIES AND RESEARCH CENTERS DEVELOPING CANCER DIAGNOSTIC TECHNOLOGIES AND APPLICATIONS

L1ST OF TABLES

Tumor Marker Classification
Major Companies Developing or Marketing ACTH Tests
Major Companies Developing or Marketing AFP Tests
Major Companies Developing or Marketing Beta-2 Microglobulin Tests
Major Companies Developing or Marketing CA 15-3/27.29 Tests
Major Companies Developing or Marketing CA 19-9 Tests
Major Companies Developing or Marketing CA 125 Tests
Major Companies Developing or Marketing Calcitonin Tests
Major Companies Developing or Marketing CEA Tests
Major Companies Developing or Marketing Estrogen Receptor Tests
Major Companies Developing or Marketing Progesterone Receptor Tests
Major Companies Developing or Marketing Ferritin Tests
Major Companies Developing or Marketing Gastrin Tests
Major Companies Developing or Marketing HCG Tests
Major Companies Developing or Marketing 1nsulin Tests
Major Companies Developing or Marketing NSE Tests
Major Companies Developing or Marketing Occult Blood Tests
Major Companies Developing or Marketing PAP Smear/HP5 Tests
Major Companies Developing or Marketing PAP Tests

Major Companies Developing or Marketing PSA Tests
Major Companies Developing or Marketing Lymphocyte Subclassification Tests
Biochemical Markers Potential Applications 1n Cancer Diagnosis
Oncogenes Potential Applications 1n Cancer Diagnosis
Major Companies Developing or Marketing Oncogene Tests
Growth Factors Potential Applications 1n Cancer Diagnosis
Colony Stimulating Factors Potential Applications in Cancer Diagnosis
Lymphokines Potential Applications 1n Cancer Diagnosis

1 IMMUNOHISTOCHEMICAL STAINS POTENTIAL APPLICATIONS IN CANCER DIAGNOSIS

Executive Summary Table: U.K., Total Tumor Marker Test 5olume and Sales Forecast by Market Segment

U.K., Estimated Cancer Death Rates Per 100,000 Population

U.K., Laboratories Performing Tumor Marker Tests by Market Segment

U.K., Hospital Laboratories Performing Tumor Marker Tests by Bed Size

U.K., Commercial/Private Laboratories Performing Tumor Marker Tests by Annual Test 5olume

U.K., Total Tumor Marker Testing 5olume Forecast by Market Segment

U.K., All Market Segments Major Tumor Marker Test 5olume Forecast

U.K., Hospital Laboratories Major Tumor Marker Test 5olume Forecast by Test

U.K., Commercial/Private Laboratories Major Tumor Marker Test 5olume Forecast

U.K., Total Tumor Marker Sales Forecast by Market Segment

U.K., All Market Segments Major Tumor Marker Sales Forecast by Test

U.K., Hospital Laboratories Major Tumor Marker Sales Forecast by Test

U.K., Commercial/Private Laboratories Major Tumor Marker Sales Forecast by Test

U.K., ACTH Test 5olume and Diagnostics Sales Forecast by Market Segment

U.K., AFP Test 5olume and Diagnostics Sales Forecast by Market Segment

U.K., Beta-2 Microglobulin Test 5olume and Diagnostics Sales Forecast by Market Segment

U.K., CA 15-3/27.29 Test 5olume and Diagnostics Sales Forecast by Market Segment

U.K., CA 19-9 Test 5olume and Diagnostics Sales Forecast by Market Segment

U.K., CA-125 Test 5olume and Diagnostics Sales Forecast by Market Segment

U.K., Calcitonin Test 5olume and Diagnostics Sales Forecast by Market Segment

U.K., CEA Test 5olume and Diagnostics Sales Forecast by Market Segment

U.K., Chromogranin Test 5olume and Diagnostics Sales Forecast by Market Segment

U.K., Colon-Specific Antigen Test 5olume and Diagnostics Sales by Market Segment

U.K., Cytokeratins Test 5olume and Diagnostics Sales Forecast by Market Segment

U.K., Estrogen Receptor Test 5olume and Diagnostics Sales Forecast by Market Segment

U.K., Ferritin Test 5olume and Diagnostics Sales Forecast by Market Segment

U.K., Gastrin Test 5olume and Diagnostics Sales Forecast by Market Segment

U.K., HCG Test 5olume and Diagnostics Sales Forecast by Market Segment

U.K., 1nsulin Test 5olume and Diagnostics Sales Forecast by Market Segment

U.K., Lymphocyte Subtyping Test 5olume and Diagnostics Sales Forecast by Market Segment

U.K., NSE Test 5olume and Diagnostics Sales Forecast by Market Segment

U.K., Occult Blood Test 5olume and Diagnostics Sales Forecast by Market Segment

U.K., Oncogenes Test 5olume and Diagnostics Sales Forecast by Market Segment

U.K., Pancreatic Oncofetal Antigen Test 5olume and Diagnostics Sales Forecast by Market Segment

U.K., PAP Smear Test 5olume and Diagnostics Sales Forecast by Market Segment

U.K., Parathyroid Hormone Test 5olume and Diagnostics Sales Forecast by Market Segment

U.K., Progesterone Receptor Test 5olume and Diagnostics Sales Forecast by Market Segment

U.K., PAP Test 5olume and Diagnostics Sales Forecast by Market Segment

U.K., PSA Test 5olume and Diagnostics Sales Forecast by Market Segment

U.K., S-100 Protein Test 5olume and Diagnostics Sales Forecast by Market Segment

U.K., Serotonin Test 5olume and Diagnostics Sales Forecast by Market Segment

U.K., Sialic Acid Test 5olume and Diagnostics Sales Forecast by Market Segment

U.K., Squamous Cell Carcinoma Antigen Test 5olume and Diagnostics Sales Forecast by Market Segment

U.K., TDT Test 5olume and Diagnostics Sales Forecast by Market Segment

U.K., Thymidine Kinase Test 5olume and Diagnostics Sales Forecast by Market Segment

U.K., Thyroglobulin Test 5olume and Diagnostics Sales Forecast by Market Segment

U.K., TPA Test 5olume and Diagnostics Sales Forecast by Market Segment

U.K., Total Tumor Marker Sales and Market Shares Forecast

U.K., CEA Testing Market Diagnostics Sales by Major Supplier

U.K., PSA Testing Market Diagnostics Sales by Major Supplier

I would like to order

Product name: 2017 UK Therapeutic Drug Monitoring (TDM) Market: Future Horizons and Growth Strategies--Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities

Product link: <https://marketpublishers.com/r/U3EFBAF5C95EN.html>

Price: US\$ 2,205.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/U3EFBAF5C95EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970